国际肿瘤学杂志

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (8): 696-699.doi: 10.3760/cma.j.issn.1673422X.2017.09.014

• 综述 • 上一篇    下一篇

APOBEC3B在乳腺癌中的研究进展

董荣荣, 何雪心, 季佳丽   

  1. 310000 杭州，浙江大学医学院附属第二医院肿瘤内科
  • 出版日期:2017-09-08 发布日期:2017-10-31
  • 通讯作者: 何雪心，Email: hexuexin2011@126.com E-mail:hexuexin2011@126.com

Research process of APOBEC3B in breast cancer

Dong Rongrong, He Xuexin, Ji Jiali   

  1. Department of Medical Oncology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310000, China
  • Online:2017-09-08 Published:2017-10-31
  • Contact: He Xuexin E-mail:hexuexin2011@126.com

PDF

855

摘要： 载脂蛋白B mRNA 编辑酶催化多肽（APOBEC）家族中的APOBEC3B是一类具有胞嘧啶脱氨酶活性的蛋白。研究表明APOBEC3B可以通过介导体细胞突变参与乳腺癌的发生发展，促进肿瘤转移和耐药，影响乳腺癌的治疗疗效，与乳腺癌的预后关系密切，在乳腺癌的诊断和治疗中具有潜在的临床应用价值，可为乳腺癌的治疗提供新希望。

关键词: 乳腺肿瘤, 突变, 预后, 载脂蛋白B mRNA 编辑酶催化多肽3B

Abstract: APOBEC3B is one member of APOBEC with the activity of cytosine deaminase. Researches show that APOBEC3B can take park in the development and progression of breast cancer by means of mediating the genome mutations, which can promote cancer metastasis and drug resistance, thus influencing the treatment effect of patients with cancers. APOBEC3B is closely related with clinical prognosis of breast cancer, which has a potential value in the early diagnosis and biological therapy of breast cancer and provides a new hope for the treatment of breast cancer.

Key words: Breast neoplasms, Mutation, Prognosis, Apolioprotein B mRNAediting enzyme catalytic polypeptide 3B